Background: Evidence regarding the role of non-invasive marker of airway inflammation, fractional exhaled nitric oxide (FeNO) to guide asthma treatment is equivocal. We aimed to evaluate if the use of FeNO to adjust inhaled corticosteroid treatment resulted in reduced daily corticosteroid use and lesser exacerbations.Methods: 100 patients of bronchial asthma in the age group of 12-70 years were randomised to receive inhaled corticosteroids based on either FeNO measurements (n = 50) or as per Global Initiative for Asthma (GINA) guidelines. Follow up was done every 2 months for period of 12 months. Results were compared in terms of mean daily inhaled corticosteroid use and number of exacerbations.Results: After the follow up period of 12 months, mean daily dose of ICS (SD) required in FeNO group was 267.5 mg (126.29), as opposed to control group in which mean daily dose of steroid was 320.00 mg (138.69). However this observed difference in steroid dose was statistically insignificant ( p value = 0.061). The estimated mean (SD) rate of asthma exacerbation experienced in follow up period of 12 months in FeNO group was 0.3 episodes (0.54) per patient per year (95% confidence interval, 0.145-455) and 0.4 episodes (0.61) per patient per year in control group (95% confidence interval, 0.228-572). However this difference in rate of exacerbations between the two study groups was not statistically significant ( p = 0.387).
Conclusion:FeNO guided management strategy for asthma did not result in statistically significant reduction in dose of inhaled corticosteroids or number of asthma exacerbations.
Rationale:
Obstructive sleep apnea (OSA) is often seen among obese individuals and the obesity has a linear association with MAFLD. The contribution of chronic intermittent nocturnal hypoxia of OSA and association of MAFLD with OSA is an unmet need. The present study aimed to determine the etiology, impact and association of OSA severity and nocturnal hypoxemia among patients ofChronic liver disease (CLD).
Methods:
In this study, analysis of the medical records and clinical details of the patients of CLD who had undergone polysomnography were analyzed after appropriate inclusion in study as per inclusion and exclusion criteria. After assessing the eligibility criteria, a total of 78 patients were included in the final analysis. Nocturnal hypoxemia was gauged from the baseline oxygen saturation record of study. Presence and severity of OSA were graded as per American Academy of Sleep Medicine (AASM) criteria. The primary objective of the study was to determine the association between OSA severity and nocturnal hypoxemia to the presence of Non-alcoholic Fatty Liver Disease (NAFLD). Secondary objectives were to assess the association of OSA severity and extent of nocturnal hypoxemia to the BMI and to determine the proportions of NAFLD subjects with OSA.
Results:
A total of 78 patients were screened, of which only 11 (14.1%) were female. Out of these, 56 (71.8%) were classified to MAFLD group while 22 (28.2%) were to the non-MAFLD group. The patients in MAFLD group with mean age of 56.02 years were older as compared to non-MAFLD with mean age of 51.05 years but that was not statistically different. Patients were categorized into MAFLD (
n
= 56) and non-MAFLD, representing other etiologies of CLD (
n
= 22; ethanol, chronic Hepatitis B virus (HBV), chronic Hepatitis C virus (HCV), cryptogenic, Non-cirrhosis portal fibrosis (NCPF), Primary sclerosing cholangitis (PSC), Autoimmune hepatitis (AIH), sarcoidosis, Wilson's disease). The mean BMI was significantly higher in MAFLD in comparison to non-MAFLD (34.51 ± 8.79 vs. 25.47 ± 5.75;
P
= 0.000) and also the median AHI of MAFLD group was significantly higher than the non-MAFLD 4.95 {(1.85, 25.47) vs. 0.85 (0.30, 2.72) (
P
value < 0.000)} [Table 1]. Among the desaturation indices, the number of desaturations >3% {median of 122.50 (75.00, 241.25) vs. 63.00 (13.75, 158.00),
P
value 0.009} and average desaturation {mean of (5.04 ± 2.16) vs. (3.78 ± 1.226)%,
P
value 0.002} were significantly higher in MAFLD versus non-MAFLD group [Table 2]. The AHI and all desaturation parameters, although not statistically significant, were worst in Child B [Table 3].
Conclusion:
MAFLD patients have higher prevalence and greater severity of OSA and worse nocturnal desaturation parameters as compared to non-MAFLD patients. OSA is in...
Background: There are apprehensions amongst healthcare worker (HCWs) about COVID-19. The HCWs
have been given hydroxychloroquine (HCQ) chemoprophylaxis for seven weeks as per Government of
India guidelines.
Objectives: To assess the apprehensions amongst HCWs about COVID-19 and to document accessibility,
adherence and side effects related to HCQ prophylaxis in HCWs.
Methods: A longitudinal follow up study was conducted in a tertiary care hospital. HCQ was given in the
dose of 400 mg twice on day one, and then 400 mg weekly for seven weeks. 391 HCWs were interviewed
using semi-structured questionnaire.
Results: 62.2% HCWs expressed perceived danger posted by COVID-19 infection. Doctors (54%) showed
least acceptance and paramedics (88%) showed highest acceptance to chemoprophylaxis. 17.5%
participants developed at least one of the side effects to HCQ. Females and nursing profession were
significantly associated with adverse effects. Common side effects were gastro-intestinal symptoms,
headache and abnormal mood change. Most of these were mild, not requiring any intervention. Gender,
professions and perceived threat of COVID-19 were significantly associated with acceptance and
adherence to HCQ prophylaxis.
Conclusion: Two thirds of HCWs had perceived danger due to COVID-19. Three fourth of the HCWs
accepted chemoprophylaxis and four out of five who accepted had complete adherence to prophylaxis
schedule. One out of five had developed at least one of side effects; however, most of these were mild
not requiring any intervention.
Background:HIV infection is an unfortunate consequence of a defined set of behaviors. Individuals with continued high-risk behavior either due to personality factors or due to maladaptive coping skills have higher viral loads and morbidity. Research has shown significant interactions between less effective coping styles and personality factors.Aim:This study aimed to evaluate personality traits, coping skills, and their association in male HIV-seropositive cases.Materials and Methods:This was a cross-sectional study, conducted on 86 patients. Informed consent and sociodemographic details, by a structured questionnaire, were obtained. Scales pertaining to personality factors and coping were applied. Statistical analysis was done by SPSS 16.Results:Neuroticism, extraversion, and conscientiousness traits were in the average range. Scores on openness and agreeableness were below average. The results pertaining to coping showed an overall mean score of 50.78, with the highest on physical domain and then on the philosophical domain, the lowest was in social domain. The research sample perceived their coping resources as average. Neuroticism was negatively related to all the coping styles. Extraversion showed relation with physical, emotional, social, and philosophical scales. Openness was related to philosophical and emotional scales. Agreeableness correlated with all domains of coping except the social. Conscientiousness correlated significantly with all the domains of coping.Conclusion:The various personality traits associated with male HIV-seropositive patients were identified and various coping resources used by these were also delineated. Further, the association among them was identified which can help in primary prevention and mental health professionals to have a targeted approach for counseling.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.